TABLE 1.
Patient demographics.
| Patient | Sex | Age | TNM‐stage | Sample used for |
|---|---|---|---|---|
| A | Female | 75 | pT4N1a | TEM |
| B | Male | 71 | pT3bN1b | TEM |
| C | Male | 68 | pT3b1N0 | TEM |
| 1 | Male | 74 | pT2N0 | LC‐MS/MS |
| 2 | Female | 86 | pT3bN2a | LC‐MS/MS |
| 3 | Female | 78 | pT3N0 | LC‐MS/MS |
| 4 | Female | 56 | pT4aN1b | LC‐MS/MS, ExoView, NTA |
| 5 | Female | 75 | pT3bN0 | LC‐MS/MS, WB, NTA |
| 6 | Male | 83 | T3bN0 | LC‐MS/MS, WB |
| 7 | Female | 82 | T2N0 | LC‐MS/MS |
| 8 | Female | 61 | T3cN2a | LC‐MS/MS, WB |
| 9 | Female | 74 | T3dN0 | LC‐MS/MS, WB, NTA |
| 10 | Female | 87 | T4aN0 | LC‐MS/MS |
Patient demographics and which analysis the samples were used for. Patients denoted alphabetically were not included in the proteomics, while patients denoted by numbers were included. Tandem liquid chromatography/mass spectrometry (LC‐MS/MS), Western blots (WB), Transmission electron microscopy (TEM).